Cargando…

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin

The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoenigl, Martin, Sprute, Rosanne, Egger, Matthias, Arastehfar, Amir, Cornely, Oliver A., Krause, Robert, Lass-Flörl, Cornelia, Prattes, Juergen, Spec, Andrej, Thompson, George R., Wiederhold, Nathan, Jenks, Jeffrey D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Leading Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501344/ https://www.ncbi.nlm.nih.gov/pubmed/34626339 http://dx.doi.org/10.1007/s40265-021-01611-0

Ejemplares similares

Review of the Novel Investigational Antifungal Olorofim
por: Wiederhold, Nathan P.
Publicado: (2020)

Social determinants of health as drivers of fungal disease
por: Jenks, Jeffrey D., et al.
Publicado: (2023)

123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Pappas, Peter G, et al.
Publicado: (2021)

COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
por: Arastehfar, Amir, et al.
Publicado: (2020)

EHA Endorsement of the Global Guideline for the Diagnosis and Management of Rare Mold Infection: An Initiative of the European Confederation of Medical Mycology in Cooperation With International Society for Human and Animal Mycology and American Society for Microbiology
por: Sprute, Rosanne, et al.
Publicado: (2021)

S4.1a Fusariosis: MICs, mono versus combination therapy and fosmanogepix
por: Hoenigl, Martin
Publicado: (2022)

Blood Aspergillus PCR: The Good, the Bad, and the Ugly
por: Egger, Matthias, et al.
Publicado: (2020)

Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline
por: Mok, Chi Chiu
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
por: Arastehfar, Amir, et al.
Publicado: (2020)

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022)

Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance
por: Buil, Jochem B., et al.
Publicado: (2022)

Serum Lateral Flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: A two‐centre mixed cohort study
por: Hoenigl, Martin, et al.
Publicado: (2021)

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Alexander, Barbara D, et al.
Publicado: (2020)

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

Refractory Microascus Bronchopulmonary Infection Treated with Olorofim, France
por: Faure, Emmanuel, et al.
Publicado: (2023)

Comment on: Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching
por: Grothe, Jan, et al.
Publicado: (2022)

871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Thompson, George R, et al.
Publicado: (2022)

Nutrition as a modifiable factor in the onset and progression of pulmonary function impairment in COPD: a systematic review
por: van Iersel, Lieke E J, et al.
Publicado: (2022)

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
por: Alkhazraji, Sondus, et al.
Publicado: (2020)

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia
por: Cornely, Oliver A, et al.
Publicado: (2023)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim
por: Lim, Wilson, et al.
Publicado: (2020)

In Vitro Activity of the Novel Antifungal Olorofim against Scedosporium and Lomentospora prolificans
por: Georgacopoulos, Ourania, et al.
Publicado: (2023)

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis
por: Jeck, Julia, et al.
Publicado: (2023)

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
por: Rubino, Christopher M., et al.
Publicado: (2021)

Reason and reality—identifying barriers to patient enrolment for clinical trials in invasive candidiasis
por: Sprute, Rosanne, et al.
Publicado: (2022)

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
por: Daraskevicius, Justinas, et al.
Publicado: (2022)

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
por: Phillips, Nancy A, et al.
Publicado: (2023)

The Aspergillus Lateral Flow Assay for the Diagnosis of Invasive Aspergillosis: an Update
por: Jenks, Jeffrey D., et al.
Publicado: (2020)

Longitudinal Evaluation of Plasma Cytokine Levels in Patients with Invasive Candidiasis
por: Wunsch, Stefanie, et al.
Publicado: (2021)

Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement
por: Jenks, Jeffrey D., et al.
Publicado: (2020)

Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
por: Sprute, Rosanne, et al.
Publicado: (2021)

EQUAL Trichosporon Score 2022: an ECMM score to measure QUALity of the clinical management of invasive Trichosporon infections
por: Sprute, Rosanne, et al.
Publicado: (2022)

The silent flucytosine shortage in Europe – not a distant problem
por: Sprute, Rosanne, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tlab6rc4gnpk8l24qquud0km3b